Navigation Links
INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
Date:2/21/2013

VALENCIA, Calif., Feb. 21, 2013 /PRNewswire/ -- SANGUINE BIOSCIENCES, INC. ("Sanguine"), a biotechnology company empowering patients in biomedical research, has announced the closing of its seed financing round, led by INVENT Ventures and Heliant Ventures.

Sanguine engages research subjects through social media and non-profit advocacy, and schedules blood draws, which are then processed into DNA, RNA, cells, plasma, and serum, to be used as biomedical research materials at pharmaceutical companies and research institutions. The company has developed the infrastructure to provide research subjects with information on how their samples were used, in order to ultimately increase trust and information flow back to researchers.

"Sanguine has experienced significant growth since Q4 2012, both in terms of revenues and number of research subjects. The successful completion of the laboratory and regulatory infrastructure allowed us the opportunity to open our doors to research participants, both healthy, and diagnosed with an ailment(s), and to researchers at numerous pharmaceutical companies and academic institutions.

We plan to use the funds raised in the seed round to further develop our internal infrastructure in order to safely and efficiently collect, process, document, and store up to 1,000 blood samples each month across the west coast. We are looking forward to scaling up and providing researchers with the samples they need to perform their investigations, while also providing patients with the knowledge of how their samples have impacted Personalized Medicine research."Brian Neman , CEO

"Sanguine is building products and processes that will revolutionize personalized medicine research," said INVENT CEO Bryce Knight . "We are thrilled to support Sanguine and its exceptional team through their growth at the forefront of multiple rapidly-growing markets." 

"We are very happy to jointly lead this round of investment and to be connected to a company at the forefront of its industry. Sanguine's business model achieves that unique harmony between placing the patient interests first while still generating returns for all its stakeholders," said Heliant Ventures Director Ben Weiss . "Full credit to the hard-working Sanguine team for reaching this important milestone and we look forward to supporting the company to realize its exciting growth potential."

About Sanguine BioSciences Inc.
Sanguine BioSciences is a biotechnology company bridging the gap between patients and researchers by providing transparency throughout the personalized medicine R&D process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery. (http://sanguinebio.com)

About INVENT Ventures
INVENT Ventures Inc. (OTC: IDEA) is a publicly traded venture fund that builds and invests in transformative technology businesses. INVENT primarily operates in markets of digital media, consumer Internet, and social networking, and has built six companies at various stages of development. (www.invent.vc.)

About Heliant Ventures
Established in 2012, Heliant Ventures is a venture capital fund backed by leading investors across Asia and Australia. (www.heliantventures.com)


'/>"/>
SOURCE Sanguine BioSciences, Inc.; INVENT Ventures, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Researchers invent acoustic-assisted magnetic information storage
2. Cellphone Microscope Inventor Honored with Biophotonics Technology Innovator Award
3. Cieri Media Announces New Science Series 'Bright Ideas' Focusing on Latest Inventions
4. NTUs sense-ational invention helps underwater vessels navigate with ease
5. Collegiate Inventors Honored for Innovative Science and Technology Advances
6. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
7. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
8. University of Utah physicists invent spintronic LED
9. RURO Adds Critical Level Monitoring Functionality to its Inventory Management Software FreezerPro.
10. Ocean Tomo Study Ranks Top 25 Most Inventive Illinois Companies in 2011 for Crain’s Chicago Business
11. College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" ... in China , today announced that its board ... expiration date of the plan from March 27, 2017 to March ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, ... viscous and elastic characteristics when deformed, which is identical to how the human ... absorb compressive forces and return to its natural state along a hysteresis curve, ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
Breaking Biology News(10 mins):